2型糖尿病患者循环氨基酸与大血管、微血管及死亡结局风险:ADVANCE试验结果
基于ADVANCE试验的病例-队列研究(N=3587)分析2型糖尿病患者循环氨基酸与结局的关联。在校正扩展经典危险因素后,较高的酪氨酸和丙氨酸水平与微血管疾病风险降低相关,较高的亮氨酸、组氨酸和缬氨酸水平与全因死亡风险降低相关。将全部氨基酸加入风险评分可 modestly 改善大血管和微血管事件的分类。
要点
- 校正扩展经典危险因素后,较高的酪氨酸和丙氨酸水平与微血管疾病风险降低相关。
- 较高的亮氨酸、组氨酸和缬氨酸水平与全因死亡风险降低相关。
- 将全部氨基酸加入风险评分可 modestly 改善大血管和微血管事件的分类。
核心结论
- 循环氨基酸与2型糖尿病不同主要并发症风险存在 distinct 关联。
- 低酪氨酸似乎是2型糖尿病微血管风险的标志物,独立于基本肾功能标志物。
研究设计与样本
- 病例-队列研究(N=3587),为ADVANCE研究的二次分析。
- 随访期间包括655例大血管事件、342例微血管事件(新发或恶化肾病或视网膜病变)和632例全因死亡事件。
- 采用质子NMR代谢组学在储存血浆样本中测量苯丙氨酸、异亮氨酸、谷氨酰胺、亮氨酸、丙氨酸、酪氨酸、组氨酸和缬氨酸。
- 风险比按每种氨基酸每增加1个标准差建模。
主要发现
- 校正年龄、性别和随机治疗后,苯丙氨酸与大血管疾病风险正相关,组氨酸与大血管疾病风险负相关;进一步校正扩展经典危险因素(包括eGFR和尿白蛋白/肌酐比值)后,这些关联减弱至无效。
- 校正扩展经典危险因素后,较高的酪氨酸水平与微血管疾病风险降低相关(HR 0.78;95% CI 0.67, 0.91),较高的丙氨酸水平与微血管疾病风险降低相关(HR 0.86;95% CI 0.76, 0.98)。
- 较高的亮氨酸水平与全因死亡风险降低相关(HR 0.79;95% CI 0.69, 0.90),较高的组氨酸水平与全因死亡风险降低相关(HR 0.89;95% CI 0.81, 0.99),较高的缬氨酸水平与全因死亡风险降低相关(HR 0.79;95% CI 0.70, 0.88)。
- 将全部氨基酸加入风险评分后,大血管事件的分类 modestly 改善(连续净重分类指数 +35.5%,p < 0.001),微血管事件的分类 modestly 改善(连续净重分类指数 +14.4%,p = 0.012)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESES: We aimed to quantify the association of individual circulating amino acids with macrovascular disease, microvascular disease and all-cause mortality in individuals with type 2 diabetes. METHODS: We performed a case-cohort study (N = 3587), including 655 macrovascular events, 342 microvascular events (new or worsening nephropathy or retinopathy) and 632 all-cause mortality events during follow-up, in a secondary analysis of the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) study. For this study, phenylalanine, isoleucine, glutamine, leucine, alanine, tyrosine, histidine and valine were measured in stored plasma samples by proton NMR metabolomics. Hazard ratios were modelled per SD increase in each amino acid. RESULTS: In models investigating associations and potential mechanisms, after adjusting for age, sex and randomised treatment, phenylalanine was positively, and histidine inversely, associated with macrovascular disease risk. These associations were attenuated to the null on further adjustment for extended classical risk factors (including eGFR and urinary albumin/creatinine ratio). After adjustment for extended classical risk factors, higher tyrosine and alanine levels were associated with decreased risk of microvascular disease (HR 0.78; 95% CI 0.67, 0.91 and HR 0.86; 95% CI 0.76, 0.98, respectively). Higher leucine (HR 0.79; 95% CI 0.69, 0.90), histidine (HR 0.89; 95% CI 0.81, 0.99) and valine (HR 0.79; 95% CI 0.70, 0.88) levels were associated with lower risk of mortality. Investigating the predictive ability of amino acids, addition of all amino acids to a risk score modestly improved classification of participants for macrovascular (continuous net reclassification index [NRI] +35.5%, p < 0.001) and microvascular events (continuous NRI +14.4%, p = 0.012). CONCLUSIONS/INTERPRETATION: We report distinct associations between circulating amino acids and risk of different major complications of diabetes. Low tyrosine appears to be a marker of microvascular risk in individuals with type 2 diabetes independently of fundamental markers of kidney function.
引用
- Welsh P, Rankin N, Li Q, et al. Circulating amino acids and the risk of macrovascular, microvascular and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE trial. Diabetologia. 2018. PMID: 29728717. doi:10.1007/s00125-018-4619-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。